SCHEMBL73063

SCHEMBL73063

CC(C(=O)O)(c1ccccc1)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.61
HDAC4 P56524 1/20 0.61
HDAC1 Q13547 1/20 0.61
HDAC7 Q8WUI4 1/20 0.61
HDAC2 Q92769 1/20 0.61
HDAC10 Q969S8 1/20 0.61
HDAC11 Q96DB2 1/20 0.61
HDAC8 Q9BY41 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
HDAC9 Q9UKV0 1/20 0.61
HDAC5 Q9UQL6 1/20 0.61
MAPT P10636 2/20 0.54
KMT2A Q03164 2/20 0.54
CYP1A2 P05177 2/20 0.52
CYP2C19 P33261 1/20 0.52
HIF1A Q16665 1/20 0.52
KDM4E B2RXH2 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
CYP2D6 P10635 1/20 0.48
KCNN4 O15554 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL27764653 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28079189 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28079333 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28727492 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL28079327 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
Bromomethane SCHEMBL209562 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrochloric Acid SCHEMBL3674757 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrogen Sulfide SCHEMBL28066375 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrogen Sulfide SCHEMBL27894390 0.97 HDAC3 (0.59) HDAC3HDAC4HDAC1HDAC7HDAC2
Hydrochloric Acid SCHEMBL27886095 0.95 HDAC3 (0.57) HDAC3HDAC4HDAC1HDAC7HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465699-B Method for producing amines from carbonyl compounds by transaminase reaction under salt precipitation 恩齐米克斯公司 2024-09-20 CN claimed
US-12018303-B2 Method for preparing amines from carbonyl compounds by transaminase reaction under salt precipitation ENZYMICALS AG (DE) 2024-06-25 US claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
CN-117683336-B Bamboo charcoal biodegradable conductive composite material and preparation method thereof 国际竹藤中心 2024-04-23 CN claimed
CN-117683336-A Bamboo charcoal biodegradable conductive composite material and preparation method thereof 国际竹藤中心 2024-03-12 CN claimed
CN-115282120-A Schiff base supermolecule assembled nano-particles and application thereof as delivery carrier 山东大学 2022-11-04 CN claimed
CN-114478627-A Allylation monophosphine ligand and preparation method thereof 湖北大学 2022-05-13 CN claimed
CN-113825818-A Photocurable adhesive composition 汉高知识产权控股有限责任公司 2021-12-21 CN claimed
CN-112876507-A Trisubstituted olefin tertiary phosphine compound and preparation method thereof 湖北大学 2021-06-01 CN claimed
CN-109851635-B Novel alkylated monophosphine ligand and simple preparation method thereof 湖北大学 2021-03-16 CN claimed
EP-1265849-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2002-12-18 EP claimed
CN-1334806-A Beta-amide and beta-sulfonamide carboxylic acid derivs., their preparation and their use as endothelin receptor antagonists BASF AG (DE) 2002-02-06 CN claimed
CN-1325375-A Method for racemate splitting of 2-hydroxypropionic acids BASF AG (DE) 2001-12-05 CN claimed
EP-0994707-A4 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARM INC (US) 2001-11-14 EP claimed
WO-2001070672-A2 COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2001-09-27 WO claimed
EP-0994707-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 2000-04-26 EP claimed
WO-1999007413-A1 SUBSTANCE P INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN ALGOS PHARMACEUTICAL CORPORATION (US) 1999-02-18 WO claimed
WO-1998053812-A1 INHIBITORS OF NAALADASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1998-12-03 WO claimed
US-5190946-A Piperazine compounds restore sensitivity to drug resistant cancer cells HOFFMANN-LA ROCHE INC. (US) 1993-03-02 US claimed
EP-0443569-A2 Diamine derivatives and their use in oncology F. HOFFMANN-LA ROCHE AG (CH) 1991-08-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018303-B2 Method for preparing amines from carbonyl compounds by transaminase reaction under salt precipitation GOT1, GOT2, OAT HDAC3 2044/4885HDAC4 2759/4885HDAC1 1045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.